New Delhi: Treating prostate cancer with higher doses of proton therapy over a shorter amount of time leads to similar outcomes when compared to standard dose levels and treatments-and it's safe for patients, according to a new study.
Researchers examined data on non-metastatic prostate cancer patients treated with 28 doses of proton therapy instead of the standard 44 and found that the rates of cancer control at four years was the same in both groups, with notably low rates of urologic and gastrointestinal effects from the treatment at four-year follow up.
The findings, which are the first to show patient reported outcomes for shorter courses of proton therapy in prostate cancer, appear in the International Journal of Radiation Oncology, Biology, Physics.
The shorter course of radiation is called hypofractionation, and previous studies have shown it can be effective with traditional photon radiation, but proton therapy has a few key differences.
Photon radiation typically uses multiple x-ray beams to attack a tumour target but unavoidably deposits radiation in the normal tissues beyond the target, potentially damaging those tissues as the beam exits the body.
Proton therapy is an FDA-approved treatment that is an alternative radiation treatment. It directs positively charged protons at the tumour target, where they deposit the bulk of the radiation dose, with minimal residual radiation delivered beyond the target, potentially reducing side effects and damage to surrounding tissue.
-From Our Bureau
